2022 Speakers

We are seeking for speakers to share their experience, expertise, opinions and best practices in BioFIT conferences.
If you are interested, please contact Marion Loizurot.

Learn more about BioFIT 2022 speakers

Over 60 international experts from academia, industry and biotech addressed issues to learn about the latest trends and explore hands-on approaches to tech transfer and open innovation in the field of Life Sciences, by sharing their experience and knowledge and keeping these goals in mind: Entail new partnerships, source innovative and competitive early-stage R&D projects, facilitate the emergence of collaborative projects and increase licensing opportunities in the field of Life Sciences.

Alex Hamilton

Alex Hamilton

Partner
United KingdomSyncona

Alex is a partner at Syncona. He is a Director on the Boards of SwanBio Therapeutics and Anaveon. Previously, he was a member of the Healthcare Investment Banking team at Jefferies, where he worked on a range of financings and mergers and acquisitions across the biotechnology, pharmaceutical and healthcare sectors. Alex has a PhD in Immunology from the University of Cambridge.

Alex Hamilton

Partner
United KingdomSyncona
Bart Wuurman

Bart Wuurman

CEO
BelgiumApaxen

Bart is a biotech CEO with over 30 years’ experience in innovative drug development, biotech financing, business development and licensing. He has extensive experience in working with R&D  based companies in several therapeutic areas, including cancer, inflammatory diseases and fibrosis. Bart Wuurman has contributed to successful biotech company exits in the UK and in the Netherlands and he was responsible for pharma licensing deals worth over $700 million. Bart was CEO of De Novo pharmaceuticals (UK), AM-Pharma (NL), Lanthio Pharma (NL) and Lyramid (Australia) and is Director of Hercules Pharmaceuticals. Bart was also Managing Director of DDF Ventures, a life-science focused venture fund with a portfolio of start-up companies in The Netherlands.

Bart Wuurman

CEO
BelgiumApaxen
Jerome Samson

Jerome Samson

Investment Manager
LuxembourgEuropean Investment Fund

Jerome Samson joined the European Investment Fund in 2017 as an Investment Manager, as part of the team investing across Europe in Venture Capital funds. He represents the EIF on the Advisory Boards of a diversified portfolio of funds, most of which operate in the fields of life sciences or climate & environmental impact, either with a focus on early or later stage investments. Prior to joining the EIF, he has been doing direct venture capital investments for over 10 years successively with three different Paris-based venture capital firms investing in early stage life sciences and agri-food technology companies. Jerome holds an engineering degree from the French Ecole Polytechnique and a PhD in Biology from Paris Descartes University.

Jerome Samson

Investment Manager
LuxembourgEuropean Investment Fund
Jürgen Walkenhorst

Jürgen Walkenhorst

Managing Director
GermanyLife Science Nord

Jürgen studied biology/molecular biology in Osnabrück and Aberdeen (UK). After his diploma thesis at the EMBL in Heidelberg, he worked at Genentech, Inc. (USA). He undertook his PhD-thesis at the Max-Planck-Institute for Developmental Biology in Tübingen. He joined Cellzome AG (Heidelberg, now part of GSK) as the first employee where he was instrumental in setting up the company and was later responsible for IP-issues. After a stint in the patent department of Baxter AG in Vienna, he changed to technology transfer. At Austria Wirtschaftsservice GmbH, Vienna, he was managing life science inventions developed at Austrian universities.

In 2007, he moved to PROvendis, the central technology transfer agency of the universities of the German state of North Rhine-Westphalia, where during most of his time at PROvendis, he served as a head of the Life sciences team. Except for another stay for one and a half years in Vienna, as head of technology transfer at the University of Vienna, he stayed with PROvendis until May 2022. In June 2022 he became the Managing Director of Life Science Nord, the regional industry network for medical technology, biotechnology and pharma for the German states of Hamburg and Schleswig-Holstein.

He also holds a Master´s degree in Pharmaceutical Business Development and Licensing from the University of Manchester.

Jürgen Walkenhorst

Managing Director
GermanyLife Science Nord
Vishal Sahni

Vishal Sahni

Director, Corporate Business Development & Strategy
DenmarkLundbeck

Vishal is a Director of Corporate Business Development and Strategy at H. Lundbeck A/S where he focuses on searching and evaluating pre-clinical, clinical and digital opportunities for partnering. Over the last 10+ years, Vishal led teams at several stages of the drug discovery, development and commercialization value chain at Eisai, GSK and MSD, working across Europe, the United States and Asia to support the development of small molecule-, biologics- and gene therapy-medicines.

Vishal holds a PhD in Developmental Neurobiology from University College London, a Master’s degree in Experimental Neuroscience from Imperial College London and a Bachelor’s degree in Biomedical Science from King’s College London.

Vishal Sahni

Director, Corporate Business Development & Strategy
DenmarkLundbeck
Zuzanna Brzosko

Zuzanna Brzosko

Senior Director, Corporate Strategy & External Innovation
United KingdomEli Lilly and Company

She completed her PhD and postdoctoral training in Neuroscience at Cambridge University and her undergraduate degree at Oxford University. Following her academic work, she worked in EU Pharma & Biotech equity research at Goldman Sachs. She later co-founded and was the CEO of Sixfold Bioscience prior to joining Lilly.

Zuzanna Brzosko

Senior Director, Corporate Strategy & External Innovation
United KingdomEli Lilly and Company

Contact

Marion Loizurot

Scroll to Top
  • No products in the cart.